Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Retained Earnings (2017 - 2025)

Sutro Biopharma's Retained Earnings history spans 9 years, with the latest figure at -$978.0 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 24.28% to -$978.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$978.0 million, a 24.28% decrease, with the full-year FY2025 number at -$978.0 million, down 24.28% from a year prior.
  • Retained Earnings hit -$978.0 million in Q4 2025 for Sutro Biopharma, down from -$931.2 million in the prior quarter.
  • Over the last five years, Retained Earnings for STRO hit a ceiling of $106000.0 in Q3 2024 and a floor of -$978.0 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$339.6 million across 5 years, with a median of -$276.8 million in 2021.
  • The widest YoY moves for Retained Earnings: up 1414.29% in 2024, down 3747095.24% in 2024.
  • Tracing STRO's Retained Earnings over 5 years: stood at -$333.4 million in 2021, then tumbled by 35.75% to -$452.6 million in 2022, then skyrocketed by 100.0% to $21000.0 in 2023, then crashed by 3747095.24% to -$786.9 million in 2024, then decreased by 24.28% to -$978.0 million in 2025.
  • Business Quant data shows Retained Earnings for STRO at -$978.0 million in Q4 2025, -$931.2 million in Q3 2025, and -$874.3 million in Q2 2025.